Literature DB >> 3279286

Angiotensin-converting enzyme inhibitors.

H H Rotmensch1, P H Vlasses, R K Ferguson.   

Abstract

There is convincing evidence that ACE inhibitors, alone or in combination with a diuretic, effectively lower blood pressure in patients with all grades of essential or renovascular hypertension and that they are of particular benefit as adjunctive therapy in patients with congestive heart failure. The hemodynamic, hormonal and clinical effects of the presently available ACE inhibitors, captopril and enalapril, are comparable and their side effect profiles are extremely favorable. One important difference between the two oral ACE inhibitors, however, is their pharmacokinetics; enalapril's action is slower to begin and is of longer duration. Compared with other agents, ACE inhibitors offer important advantages, among them an improved feeling of well being. It is, therefore, expected that ACE inhibitors will gain greater acceptance by patients and physicians in the future.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3279286     DOI: 10.1016/s0025-7125(16)30776-3

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  7 in total

Review 1.  Newer ACE inhibitors. A look at the future.

Authors:  A Salvetti
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 2.  Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension.

Authors:  M I Wilde; H M Bryson; K L Goa
Journal:  Pharmacoeconomics       Date:  1994-08       Impact factor: 4.981

3.  Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril.

Authors:  E G Bevan; G T McInnes; J C Aldigier; J J Conte; J P Grunfeld; S J Harper; B H Meyer; N Pauly; R Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

Review 4.  Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update.

Authors:  R C Parish; L J Miller
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

Review 5.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

Review 6.  Choosing the right ACE inhibitor. A guide to selection.

Authors:  G Leonetti; C Cuspidi
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

7.  Hypotensive effect of captopril on deoxycorticosterone acetate-salt-induced hypertensive rat is associated with gut microbiota alteration.

Authors:  Haicui Wu; Theo Y C Lam; Tim-Fat Shum; Tsung-Yu Tsai; Jiachi Chiou
Journal:  Hypertens Res       Date:  2021-12-02       Impact factor: 3.872

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.